NASDAQ:BVXVBIONDVAX PHARMA/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIONDVAX PHARMA/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.40 -0.28 (-3.65 %) (As of 04/8/2020 04:00 PM ET) Add Compare Share Today's Range$7.40Now: $7.40▼$7.9550-Day Range$5.36MA: $7.54▼$9.1552-Week Range$5.20Now: $7.40▼$13.50Volume12,900 shsAverage Volume41,611 shsMarket Capitalization$48.37 millionP/E RatioN/ADividend YieldN/ABeta1.33 ProfileAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for BIONDVAX PHARMA/S. Previous Next 2.3 Community Rank Outperform VotesBIONDVAX PHARMA/S has received 171 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBIONDVAX PHARMA/S has received 193 “underperform” votes. (Add your “underperform” vote.)Community SentimentBIONDVAX PHARMA/S has received 53.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote “Outperform” if you believe BVXV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBIONDVAX PHARMA/S does not currently pay a dividend.Dividend GrowthBIONDVAX PHARMA/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIONDVAX PHARMA/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.03% of the stock of BIONDVAX PHARMA/S is held by insiders.Percentage Held by InstitutionsOnly 7.30% of the stock of BIONDVAX PHARMA/S is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIONDVAX PHARMA/S is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIONDVAX PHARMA/S is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV Previous Symbol CUSIPN/A CIK1611747 Webhttp://www.biondvax.com/ Phone972-8930-2529Debt Debt-to-Equity RatioN/A Current Ratio25.14 Quick Ratio25.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-5.83Profitability EPS (Most Recent Fiscal Year)($3.60) Net Income$-23,410,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-109.31%Miscellaneous Employees14 Outstanding Shares6,536,000Market Cap$48.37 million Next Earnings Date6/4/2020 (Estimated) OptionableNot Optionable Receive BVXV News and Ratings via Email Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BVXV Rates by TradingView BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions How has BIONDVAX PHARMA/S's stock been impacted by COVID-19 (Coronavirus)? BIONDVAX PHARMA/S's stock was trading at $6.5350 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BVXV shares have increased by 13.2% and is now trading at $7.40. View which stocks have been most impacted by Coronavirus. When is BIONDVAX PHARMA/S's next earnings date? BIONDVAX PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for BIONDVAX PHARMA/S. Has BIONDVAX PHARMA/S been receiving favorable news coverage? Media headlines about BVXV stock have trended very negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutBIONDVAX PHARMA/S. Who are some of BIONDVAX PHARMA/S's key competitors? Some companies that are related to BIONDVAX PHARMA/S include Eiger Biopharmaceuticals (EIGR), Cabaletta Bio (CABA), Jounce Therapeutics (JNCE), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), La Jolla Pharmaceutical (LJPC), Windtree Therapeutics (WINT), Verona Pharma (TARA), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Vaxart (VXRT), LogicBio Therapeutics (LOGC), Solid Biosciences (SLDB), Cidara Therapeutics (CDTX) and Erytech Pharma (ERYP). What other stocks do shareholders of BIONDVAX PHARMA/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), BIOLINERX LTD/S (BLRX), Agilent Technologies (A), Enterprise Products Partners (EPD), AT&T (T), NovaBay Pharmaceuticals (NBY) and Akari Therapeutics (AKTX). Who are BIONDVAX PHARMA/S's key executives? BIONDVAX PHARMA/S's management team includes the following people: Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)Dr. Shimon Hassin, Chief Operating OfficerMr. Elad Mark, Head of Site & Process Devel. When did BIONDVAX PHARMA/S IPO? (BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. What is BIONDVAX PHARMA/S's stock symbol? BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV." How do I buy shares of BIONDVAX PHARMA/S? Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BIONDVAX PHARMA/S's stock price today? One share of BVXV stock can currently be purchased for approximately $7.40. How big of a company is BIONDVAX PHARMA/S? BIONDVAX PHARMA/S has a market capitalization of $48.37 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe. View additional information about BIONDVAX PHARMA/S. What is BIONDVAX PHARMA/S's official website? The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/. How can I contact BIONDVAX PHARMA/S? BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: What are retained earnings?
